Induced Pluripotent Stem Cells from Human Kidney

Rogers, Ian

doi:10.1681/asn.2011050501

Cited by 6 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies suggested that tissue-specific iPSCs retain the epigenetic pattern of the original parent cells. Song et al [56] and Zhou et al [57,58] generated iPSCs from normal human kidney mesangial cells and exfoliated renal tubular cells present in urine of healthy donors, respectively, leading the way to developing a tissue-specific iPSC therapy for kidney disease [59] . Moreover, the general reprogramming efficiency from urine was higher than for other methods, between 0.1 and 4%.…”

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Recent Progress in Stem Cell Therapy for Diabetic Nephropathy

Liu

Tang²

2015

Kidney Dis

View full text Add to dashboard Cite

show abstract

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Recent Progress in Stem Cell Therapy for Diabetic Nephropathy

Liu

Tang²

2015

Kidney Dis

View full text Add to dashboard Cite

show abstract

“…iPSCs were generated from normal human mesangial cells [ 169 ] and exfoliated tubular cells collected from urine of healthy donors [ 170 ], paving the way to employment of tissue-specific iPSC therapy for renal disorders [ 171 ].…”

Section: Stem Cells and Extracellular Vesicles As Therapeutic Tools F...mentioning

confidence: 99%

Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis

Quaglia

Merlotti

Fornara

et al. 2022

IJMS

View full text Add to dashboard Cite

Current treatment of primary and secondary glomerulopathies is hampered by many limits and a significant proportion of these disorders still evolves towards end-stage renal disease. A possible answer to this unmet challenge could be represented by therapies with stem cells, which include a variety of progenitor cell types derived from embryonic or adult tissues. Stem cell self-renewal and multi-lineage differentiation ability explain their potential to protect and regenerate injured cells, including kidney tubular cells, podocytes and endothelial cells. In addition, a broad spectrum of anti-inflammatory and immunomodulatory actions appears to interfere with the pathogenic mechanisms of glomerulonephritis. Of note, mesenchymal stromal cells have been particularly investigated as therapy for Lupus Nephritis and Diabetic Nephropathy, whereas initial evidence suggest their beneficial effects in primary glomerulopathies such as IgA nephritis. Extracellular vesicles mediate a complex intercellular communication network, shuttling proteins, nucleic acids and other bioactive molecules from origin to target cells to modulate their functions. Stem cell-derived extracellular vesicles recapitulate beneficial cytoprotective, reparative and immunomodulatory properties of parental cells and are increasingly recognized as a cell-free alternative to stem cell-based therapies for different diseases including glomerulonephritis, also considering the low risk for potential adverse effects such as maldifferentiation and tumorigenesis. We herein summarize the renoprotective potential of therapies with stem cells and extracellular vesicles derived from progenitor cells in glomerulonephritis, with a focus on their different mechanisms of actions. Technological progress and growing knowledge are paving the way for wider clinical application of regenerative medicine to primary and secondary glomerulonephritis: this multi-level, pleiotropic therapy may open new scenarios overcoming the limits and side effects of traditional treatments, although the promising results of experimental models need to be confirmed in the clinical setting.

show abstract

“…Tissue-specific iPSCs, such as renal-derived iPSCs, maybe more efficiently differentiated into mature kidney cells than unrelated tissue iPSCs or even ES cells 65 . Song et al 66 successfully induced human mesangial cells into pluripotent stem cells through four defined transcription factors, OCT4, SOX2, KLF4, and c-Myc, and confirmed that iPSCs have similar biological morphology and gene expression to ES cells.…”

Section: Induced Pluripotent Stem Cellsmentioning

confidence: 99%

Concise review: current trends on applications of stem cells in diabetic nephropathy

Wen

Pan

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Diabetic nephropathy, with high prevalence, is the main cause of renal failure in diabetic patients. The strategies for treating DN are limited with not only high cost but an unsatisfied effect. Therefore, the effective treatment of DN needs to be explored urgently. In recent years, due to their self-renewal ability and multi-directional differentiation potential, stem cells have exerted therapeutic effects in many diseases, such as graft-versus-host disease, autoimmune diseases, pancreatic diseases, and even acute kidney injury. With the development of stem cell technology, stem cell-based regenerative medicine has been tried to be applied to the treatment of DN. Related stem cells include embryonic stem cells, induced pluripotent stem cells, mesenchymal cells, and endothelial progenitor cells. Undoubtedly, stem cell transplantation has achieved certain results in the treatment of DN animal models. However, stem cell therapy still remains certain thorny issues during treatment. For instance, poor engraftment and limited differentiation of stem cells caused by the diabetic microenvironment, differentiation into unwanted cell lineages, and malignant transformation or genetic aberrations of stem cells. At present, various researches on the therapeutic effects of stem cells in DN with different opinions are reported and the specific mechanism of stem cells is still unclear. We review here the potential mechanism of stem cells as new therapeutic agents in the treatment of DN. Also, we review recent findings and updated information about not only the utilization of stem cells on DN in both preclinical and clinical trials but limitations and future expectations of stem cell-based therapy for DN.

show abstract

Induced Pluripotent Stem Cells from Human Kidney

Cited by 6 publications

References 22 publications

Recent Progress in Stem Cell Therapy for Diabetic Nephropathy

Recent Progress in Stem Cell Therapy for Diabetic Nephropathy

Extracellular Vesicles Released from Stem Cells as a New Therapeutic Strategy for Primary and Secondary Glomerulonephritis

Concise review: current trends on applications of stem cells in diabetic nephropathy

Contact Info

Product

Resources

About